Ratko Djukanović, Paul Brinkman, Johan Kolmert, Cristina Gomez, James Schofield, Joost Brandsma, Andy Shapanis, Paul J S Skipp, Anthony Postle, Craig Wheelock, Sven-Erik Dahlen, Peter J Sterk, Thomas Brown, David J Jackson, Adel Mansur, Ian Pavord, Mitesh Patel, Christopher Brightling, Salman Siddiqui, Peter Bradding, Ian Sabroe, Dinesh Saralaya, Livingstone Chishimba, Joanna Porter, Douglas Robinson, Stephen Fowler, Peter H Howarth, Louisa Little, Thomas Oliver, Kayleigh Hill, Louise Stanton, Alexander Allen, Deborah Ellis, Gareth Griffiths, Tim Harrison, Ayobami Akenroye, Jessica Lasky-Su, Liam Heaney, Rekha Chaudhuri, Ramesh Kurukulaaratchy
BACKGROUND: The anti-IgE monoclonal, omalizumab, is widely used for severe asthma. This study aimed to identify biomarkers that predict clinical improvement during one year of omalizumab treatment. METHODS: 1-year, open-label, S tudy o f M echanisms of action of O malizumab in S evere A sthma ( SoMOSA ) involving 216 severe (GINA step 4/5) uncontrolled atopic asthmatics (≥2 severe exacerbations in previous year) on high-dose inhaled corticosteroids, long-acting β-agonists, ± mOCS...
April 18, 2024: American Journal of Respiratory and Critical Care Medicine